23 November 2015

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology announces that, since the last update in May 2015, there have been no changes to the numbers of shares block listed in respect of the Company's two option plans. All ordinary shares of 0.2 pence each.

The table below provides further detail.

Name of company: Futura Medical plc
Name of scheme: Unapproved Share Option Scheme ("USOS")

EMI Share Option Scheme ("EMI")
Period of return: From: 12 May 2015
To: 23 November 2015
Number and class of securities not issued under the scheme(s) USOS: 1,440,600
EMI: 1,394,141
Total: 2,834,741
Number of securities issued under the scheme(s) during the period USOS: Nil
  EMI: Nil
Number of securities lapsed under the scheme(s) during the period USOS: Nil
  EMI: Nil
Balance under the scheme(s) of securities not yet issued at the end of the period USOS: 1,440,600
EMI: 1,394,141
Total: 2,834,741
Number and class of securities originally admitted and the date of admission USOS: 814,424 on 25 May 2011 and 1,202,280 on 8 October 2013
USOS Total: 2,016,704
EMI: 1,520,576 on 25 May 2011 and 1,467,720 on 8 October 2013
EMI Total: 2,988,296
Total: 5,005,000
Name of contact: Derek Martin, Chief Financial Officer
Telephone number of contact: +44 (0) 1483 685 670


For further information please contact:

Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
+44 (0) 1483 685 670

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Mark Court / Sophie Wills /
Stephanie Watson / Tilly Abraham
Tel: +44 (0) 20 7466 5000


Notes to editors:

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.